The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas.
10.3348/kjr.2015.16.6.1283
- Author:
Tae Won CHOI
1
;
Hyo Cheol KIM
;
Jeong Hoon LEE
;
Su Jong YU
;
Beomsik KANG
;
Saebeom HUR
;
Myungsu LEE
;
Hwan Jun JAE
;
Jin Wook CHUNG
Author Information
1. Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea. angiointervention@gmail.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Hepatocellular carcinoma;
Chemoembolization;
Liver cirrhosis;
Liver failure;
Safety
- MeSH:
Adult;
Aged;
Alanine Transaminase/metabolism;
Aspartate Aminotransferases/metabolism;
Carcinoma, Hepatocellular/mortality/*pathology/therapy;
Chemoembolization, Therapeutic/adverse effects;
Female;
Hepatic Encephalopathy/etiology;
Humans;
Length of Stay;
Liver Neoplasms/mortality/*pathology/therapy;
Liver Transplantation;
Male;
Middle Aged;
Proportional Hazards Models;
Severity of Illness Index;
Survival Rate;
Treatment Outcome;
Tumor Burden
- From:Korean Journal of Radiology
2015;16(6):1283-1293
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the safety and clinical outcomes of chemoembolization in Child-Pugh class C patients with hepatocellular carcinomas (HCC). MATERIALS AND METHODS: The study comprised 55 patients with HCC who were classified as Child-Pugh class C and who underwent initial chemoembolization between January 2003 and December 2012. Selective chemoembolization was performed in all technically feasible cases to minimize procedure-related complications. All adverse events within 30 days were recorded using the Common Terminology Criteria for Adverse Events (CTCAE). The tumor response to chemoembolization was evaluated using the modified Response Evaluation Criteria In Solid Tumors. RESULTS: Thirty (54.5%) patients were within the Milan criteria, and 25 (45.5%) were beyond. The mortality of study subjects at 30 days was 5.5%. Major complications were observed in five (9.1%) patients who were all beyond the Milan criteria: two hepatic failures, one hepatic encephalopathy, and two CTCAE grade 3 increases in aspartate aminotransferase/alanine aminotransferase abnormality. The mean length of hospitalization was 6.3 ± 8.3 days (standard deviation), and 18 (32.7%) patients were discharged on the next day after chemoembolization. The tumor responses of the patients who met the Milan criteria were significantly higher (p = 0.014) than those of the patients who did not. The overall median survival was 7.1 months (95% confidence interval: 4.4-9.8 months). CONCLUSION: Even in patients with Child-Pugh class C, chemoembolization can be performed safely with a selective technique in selected cases with a small tumor burden.
